- Home
- CWK vs NVCR Comparison
CWK vs NVCR Comparison
Compare CWK & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWK
- NVCR
- Stock Information
- Founded
- CWK 1784
- NVCR 2000
- Country
- CWK United Kingdom
- NVCR Jersey
- Employees
- CWK N/A
- NVCR N/A
- Industry
- CWK Real Estate
- NVCR Medical/Dental Instruments
- Sector
- CWK Finance
- NVCR Health Care
- Exchange
- CWK Nasdaq
- NVCR Nasdaq
- Market Cap
- CWK 3.3B
- NVCR 3.0B
- IPO Year
- CWK 2018
- NVCR 2015
- Fundamental
- Price
- CWK $14.46
- NVCR $33.69
- Analyst Decision
- CWK Hold
- NVCR Buy
- Analyst Count
- CWK 5
- NVCR 5
- Target Price
- CWK $15.25
- NVCR $33.40
- AVG Volume (30 Days)
- CWK 1.4M
- NVCR 1.8M
- Earning Date
- CWK 11-04-2024
- NVCR 10-30-2024
- Dividend Yield
- CWK N/A
- NVCR N/A
- EPS Growth
- CWK N/A
- NVCR N/A
- EPS
- CWK 0.38
- NVCR N/A
- Revenue
- CWK $9,369,400,000.00
- NVCR $577,738,000.00
- Revenue This Year
- CWK $1.16
- NVCR $19.13
- Revenue Next Year
- CWK $6.47
- NVCR $5.33
- P/E Ratio
- CWK $38.93
- NVCR N/A
- Revenue Growth
- CWK N/A
- NVCR 14.63
- 52 Week Low
- CWK $9.24
- NVCR $11.70
- 52 Week High
- CWK $16.11
- NVCR $34.00
- Technical
- Relative Strength Index (RSI)
- CWK 47.61
- NVCR 71.04
- Support Level
- CWK $14.75
- NVCR $31.45
- Resistance Level
- CWK $15.46
- NVCR $34.00
- Average True Range (ATR)
- CWK 0.36
- NVCR 2.49
- MACD
- CWK -0.11
- NVCR 0.45
- Stochastic Oscillator
- CWK 9.91
- NVCR 92.37
About CWK Cushman & Wakefield plc
Cushman & Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such valuation, project management, and facilities management.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.